Skip to main content

Acurx Pharmaceuticals, Inc.

ACXP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001736243

No open-market purchases or sales by Acurx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 18 institutions reported holding it in 13F filings for Q2 2026, worth $185.5K in total; no superinvestor holds it.

Q1 2026 vs. Q4 2025

How the institutions holding Acurx Pharmaceuticals, Inc. changed between Q4 2025 and Q1 2026.

All holders in Q1 2026All holders in Q4 2025

13F holders of ACXP: Q4 2025 compared with Q1 2026
MeasureQ4 2025Of which not filed for Q1 2026Q1 2026Change
Holders18121+4
Shares138.6K23.3K181.9K+66.5K (+57.7%)
Value$345.2K$58.0K$674.2K+$387.0K (+134.8%)

1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (7)

Institutions that held Acurx Pharmaceuticals, Inc. at the end of Q1 2026 but not at the end of Q4 2025.

Institutions new to ACXP in Q1 2026
InstitutionSharesValue% of portfolio
Vanguard Capital Management LLC31,099$115.4K0.00%
Cambridge Investment Research Advisors, Inc.20,000$74.0K0.00%
Vanguard Fiduciary Trust Co16,205$60.1K0.00%
Westside Investment Management, Inc.1,650$6.12K0.00%
McGuire Capital Advisors Inc1,000$3.71K0.00%
Barclays PLC380$1.41K0.00%
Advisory Services Network, LLC59$2190.00%

Sold out (3)

Institutions that held Acurx Pharmaceuticals, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.

Institutions that sold out of ACXP in Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
Millennium Management LLC41,427$103.2K
Northern Trust Corp16,914$42.1K
Bank of America Corp17$42

Not filed for Q1 2026 yet (1)

Institutions that held Acurx Pharmaceuticals, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ACXP in Q4 2025 that haven't filed for Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
Vanguard Group Inc23,280$58.0K